Donkey Oil-Based Ketogenic Diet Prevents Tumor Progression by Regulating Intratumor Inflammation, Metastasis and Angiogenesis in CT26 Tumor-Bearing Mice

  • Genes (Basel). 2023 Apr 30;14(5):1024. doi: 10.3390/genes14051024.
Huachen Zhang  1 Lan Xie  1 Ning Zhang  2 Xingzhen Qi  1 Ting Lu  1 Jingya Xing  3 Muhammad Faheem Akhtar  1 Lanjie Li  4 Guiqin Liu  1
Affiliations
  • 1. College of Agronomy, Shandong Engineering Technology Research Center for Efficient Breeding and Ecological Feeding of Black Donkey, Shandong Donkey Industry Technology Collaborative Innovation Center, Liaocheng University, Liaocheng 252000, China.
  • 2. Biopharmaceutical Research Institute, Liaocheng University, Liaocheng 252000, China.
  • 3. Inner Mongolia Key Laboratory of Equine Genetics, Breeding and Reproduction, Equine Research Center, College of Animal Science, Inner Mongolia Agricultural University, Hohhot 010018, China.
  • 4. Office of International Programs, Liaocheng University, Liaocheng 252000, China.
Abstract

Colon Cancer is one of the typical malignant tumors, and its prevalence has increased yearly. The ketogenic diet (KD) is a low-carbohydrate and high-fat dietary regimen that inhibits tumor growth. Donkey oil (DO) is a product with a high nutrient content and a high bioavailability of unsaturated fatty acids. Current research investigated the impact of the DO-based KD (DOKD) on CT26 colon Cancer in vivo. Our findings revealed that DOKD administration significantly lowered CT26+ tumor cell growth in mice, and the blood β-hydroxybutyrate levels in the DOKD group was significantly higher than those in the natural diet group. Western blot results showed that DOKD significantly down-regulated Src, hypoxia inducible factor-1α (HIF-1α), extracellular signal-related kinases 1 and 2 (ERK1/2), snail, neural Cadherin (N-Cadherin), vimentin, matrix metallopeptidase 9 (MMP9), signal transducer and activator of transcription 3 (STAT3), and vascular endothelial growth factor A (VEGFA), and it significantly up-regulated the expressions of SIRT3, S100a9, interleukin (IL)-17, nuclear factor-kappaB (NF-κB) p65, Toll-like Receptor 4 (TLR4), MyD88, and tumor necrosis factor-α. Meanwhile, in vitro validation results showed that LW6 (a HIF-1α inhibitor) significantly down-regulated the expressions of HIF-1α, N-Cadherin, vimentin, MMP9, and VEGFA, which supported those of the in vivo findings. Furthermore, we found that DOKD inhibited CT26+ tumor cell growth by regulating inflammation, metastasis, and angiogenesis by activating the IL-17/TLR4/NF-κB p65 pathway and inhibiting the activation of the Src/HIF-1α/ERK1/2/Snail/N-Cadherin/Vimentin/MMP9 and ERK1/2/HIF-1α/STAT3/VEGFA pathways. Our findings suggest that DOKD may suppress colon Cancer progression and help prevent colon Cancer cachexia.

Keywords
CT26+; HIF-1α; colon cancer; donkey oil; ketogenic diet.
Products
Inhibitors & Agonists
Other Products